血小板減少症の世界市場レポート 2025年

血小板減少症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で62億9,000万米ドルに成長します。予測期間中の成長は、血小板減少症の有病率の上昇、ヘルスケア支出の増加、世界の治療法の拡大、血液疾患の発生率の上昇、高齢化人口の増加などに起因すると考えられます。主な動向としては、新規トロンボポエチン受容体作動薬の採用、診断技術の向上、遺伝子治療の進歩、モノクローナル抗体治療の進歩、患者モニタリング技術の強化、個別化医療アプローチ、革新的治療のための臨床試験の進行などが挙げられます。

自己免疫疾患の有病率の上昇は、血小板減少症市場の成長に大きな影響を与えています。自己免疫疾患は、免疫系が誤って身体自身の細胞を標的とし、様々な臓器やシステムの炎症や損傷につながることで発生します。場合によっては、自己免疫疾患は、免疫系が血小板を破壊したり、骨髄での血小板の産生を損なったりする血小板減少症という状態をもたらします。このため、血小板減少に効果的に対処し、患者の転帰全体を改善できる治療に対する需要が高まっています。2024年11月のVersorgungsatlas.deのデータによると、ドイツでは2022年に630万人以上の被保険者が少なくとも1つの自己免疫疾患と診断されており、これらの疾患の負担が増大していることを示しています。このような自己免疫疾患の増加は、血小板減少症市場の拡大に寄与しています。

自己免疫疾患の増加は、血小板減少症を管理するためにデザインされた静脈内治療の進歩も後押ししています。静脈内治療は、血小板数を改善することによって迅速な救済を提供するもので、特に重症例や慢性例の管理には極めて重要です。これらの治療法は出血のリスクを軽減し、治療への反応を早めることで、患者の緊急のニーズに応えるものです。特筆すべき例として、アルジェンクスSEは2024年3月に日本の厚生労働省から、成人の原発性免疫異常症（ITP）に対する静注療法であるVYVGARTの承認を取得しました。この承認は、自己免疫疾患患者に対して迅速かつ持続的な血小板反応をもたらす標的治療を提供する、重要な進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界血小板減少症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血小板減少症市場：成長率分析
• 世界の血小板減少症市場の実績：規模と成長, 2019-2024
• 世界の血小板減少症市場の予測：規模と成長, 2024-2029, 2034F
• 世界血小板減少症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血小板減少症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性血小板減少症
• 血栓性血小板減少症
• 薬物誘発性血小板減少症
• 世界の血小板減少症市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダナゾール
• 静脈内免疫グロブリン
• リツキシマブ
• エルトロンボパグ
• ロミプロスチム
• 脾臓摘出術
• コルチコステロイド
• その他の薬物
• 世界の血小板減少症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の血小板減少症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の血小板減少症市場特発性血小板減少性紫斑病（ITP）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性ITP
• 慢性ITP
• 世界の血小板減少症市場血栓性血小板減少性紫斑病（TTP）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 先天性TTP（遺伝性ADAMTS13欠損症）
• 獲得性TTP（免疫介在性）
• 世界の血小板減少症市場、薬剤誘発性血小板減少症（DITP）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘパリン誘発性血小板減少症（ヒット）
• 化学療法誘発性血小板減少症
• その他の薬関連血小板減少症

第7章 地域別・国別分析

• 世界の血小板減少症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血小板減少症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血小板減少症市場：競合情勢
• 血小板減少症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Swedish Orphan Biovitrum AB
• Argenx SE
• GC Pharma
• Biotest AG
• UCB Biopharma
• Rigel Pharmaceuticals
• Millennium Pharmaceuticals
• Keros Therapeutics Inc.
• Baxalta

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血小板減少症市場2029：新たな機会を提供する国
• 血小板減少症市場2029：新たな機会を提供するセグメント
• 血小板減少症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Thrombocytopenia refers to a medical condition characterized by an abnormally low platelet count in the blood, which increases the risk of excessive bleeding. Causes include bone marrow disorders, autoimmune diseases, and certain medications. Symptoms involve easy bruising, prolonged bleeding, and petechiae (small red spots on the skin).

The main types of thrombocytopenia are idiopathic thrombocytopenic, thrombotic thrombocytopenic, and drug-induced thrombocytopenia. Idiopathic thrombocytopenic is a condition where the immune system mistakenly attacks and destroys platelets, which play a crucial role in blood clotting. The key drugs used include danazol, intravenous immune globulin, rituximab, eltrombopag, romiplostim, splenectomy, corticosteroids, and others. The various routes of administration are oral, parenteral, and others and are used by several end users, such as hospitals, specialty clinics, homecare, and others.

The thrombocytopenia market research report is one of a series of new reports from The Business Research Company that provides thrombocytopenia market statistics, including the thrombocytopenia industry's global market size, regional shares, competitors with a thrombocytopenia market share, detailed thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombocytopenia industry. This thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thrombocytopenia market size has grown strongly in recent years. It will grow from $4.38 billion in 2024 to $4.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune disorders, the rise in chronic liver disease incidences, greater healthcare service penetration, expansion of healthcare infrastructure, and increased government support.

The thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to the rising prevalence of thrombocytopenia, increasing healthcare expenditure, the global expansion of therapies, a higher incidence of blood disorders, and the growing aging population. Key trends include the adoption of novel thrombopoietin receptor agonists, improved diagnostic techniques, advancements in gene therapies, progress in monoclonal antibody treatments, enhanced patient monitoring technologies, personalized medicine approaches, and ongoing clinical trials for innovative therapies.

The rising prevalence of autoimmune diseases is significantly influencing the growth of the thrombocytopenia market. Autoimmune diseases occur when the immune system mistakenly targets the body's own cells, leading to inflammation and damage to various organs and systems. In some cases, autoimmune diseases result in thrombocytopenia, a condition where the immune system destroys platelets or impairs their production in the bone marrow. This is driving the demand for treatments that can effectively address platelet depletion and improve overall patient outcomes. According to data from Versorgungsatlas.de in November 2024, over 6.3 million insured individuals in Germany were diagnosed with at least one autoimmune disease in 2022, demonstrating a growing burden of these conditions. This increase in autoimmune diseases contributes to the expanding thrombocytopenia market.

The rise in autoimmune diseases is also propelling advancements in intravenous therapies designed to manage thrombocytopenia. Intravenous treatments offer rapid relief by improving platelet counts, which is crucial in managing the condition, particularly in severe or chronic cases. These therapies reduce the risk of bleeding and accelerate the response to treatment, addressing the urgent needs of patients. A notable example is Argenx SE's approval from Japan's Ministry of Health, Labor, and Welfare (MHLW) in March 2024 for VYVGART, an intravenous therapy for adults with primary immune thrombocytopenia (ITP). This approval represents an important advancement, offering targeted treatment that provides quick, sustained platelet response for patients with autoimmune diseases.

In December 2024, Keros Therapeutics and Takeda Pharmaceutical Industries Ltd. partnered to develop elritercept, a therapy aimed at addressing thrombocytopenia and other rare diseases related to dysfunctional TGF-B signaling. This collaboration reflects the ongoing efforts to innovate and meet the unmet needs of patients affected by autoimmune-related thrombocytopenia, reinforcing the demand for new, effective treatment options.

Major players in the thrombocytopenia market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Swedish Orphan Biovitrum AB, Argenx SE, GC Pharma, Biotest AG, UCB Biopharma, Rigel Pharmaceuticals, Millennium Pharmaceuticals, Keros Therapeutics Inc., and Baxalta.

North America was the largest region in the thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombocytopenia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits, supportive care products, and research and development products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombocytopenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombocytopenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombocytopenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombocytopenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Idiopathic Thrombocytopenic; Thrombotic Thrombocytopenic; Drug-Induced Thrombocytopenia
• 2) By Drugs: Danazol; Intravenous Immune Globulin; Rituximab; Eltrombopag; Romiplostim; Splenectomy; Corticosteroid; Other Drugs
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Idiopathic Thrombocytopenic Purpura (ITP): Acute ITP; Chronic ITP
• 2) By Thrombotic Thrombocytopenic Purpura (TTP): Congenital TTP (Hereditary ADAMTS13 Deficiency); Acquired TTP (Immune-Mediated)
• 3) By Drug-Induced Thrombocytopenia (DITP): Heparin-Induced Thrombocytopenia (HIT); Chemotherapy-Induced Thrombocytopenia; Other Medication-Related Thrombocytopenia
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bayer AG; Sanofi S.A.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thrombocytopenia Market Characteristics

3. Thrombocytopenia Market Trends And Strategies

4. Thrombocytopenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Thrombocytopenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Thrombocytopenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Thrombocytopenia Market Growth Rate Analysis
• 5.4. Global Thrombocytopenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Thrombocytopenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Thrombocytopenia Total Addressable Market (TAM)

6. Thrombocytopenia Market Segmentation

• 6.1. Global Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Thrombocytopenic
• Thrombotic Thrombocytopenic
• Drug-Induced Thrombocytopenia
• 6.2. Global Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Danazol
• Intravenous Immune Globulin
• Rituximab
• Eltrombopag
• Romiplostim
• Splenectomy
• Corticosteroid
• Other Drugs
• 6.3. Global Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Thrombocytopenia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.5. Global Thrombocytopenia Market, Sub-Segmentation Of Idiopathic Thrombocytopenic Purpura (ITP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute ITP
• Chronic ITP
• 6.6. Global Thrombocytopenia Market, Sub-Segmentation Of Thrombotic Thrombocytopenic Purpura (TTP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital TTP (Hereditary ADAMTS13 Deficiency)
• Acquired TTP (Immune-Mediated)
• 6.7. Global Thrombocytopenia Market, Sub-Segmentation Of Drug-Induced Thrombocytopenia (DITP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heparin-Induced Thrombocytopenia (HIT)
• Chemotherapy-Induced Thrombocytopenia
• Other Medication-Related Thrombocytopenia

7. Thrombocytopenia Market Regional And Country Analysis

• 7.1. Global Thrombocytopenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Thrombocytopenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thrombocytopenia Market

• 8.1. Asia-Pacific Thrombocytopenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thrombocytopenia Market

• 9.1. China Thrombocytopenia Market Overview
• 9.2. China Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thrombocytopenia Market

• 10.1. India Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thrombocytopenia Market

• 11.1. Japan Thrombocytopenia Market Overview
• 11.2. Japan Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thrombocytopenia Market

• 12.1. Australia Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thrombocytopenia Market

• 13.1. Indonesia Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thrombocytopenia Market

• 14.1. South Korea Thrombocytopenia Market Overview
• 14.2. South Korea Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thrombocytopenia Market

• 15.1. Western Europe Thrombocytopenia Market Overview
• 15.2. Western Europe Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thrombocytopenia Market

• 16.1. UK Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thrombocytopenia Market

• 17.1. Germany Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thrombocytopenia Market

• 18.1. France Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thrombocytopenia Market

• 19.1. Italy Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thrombocytopenia Market

• 20.1. Spain Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thrombocytopenia Market

• 21.1. Eastern Europe Thrombocytopenia Market Overview
• 21.2. Eastern Europe Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thrombocytopenia Market

• 22.1. Russia Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thrombocytopenia Market

• 23.1. North America Thrombocytopenia Market Overview
• 23.2. North America Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thrombocytopenia Market

• 24.1. USA Thrombocytopenia Market Overview
• 24.2. USA Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thrombocytopenia Market

• 25.1. Canada Thrombocytopenia Market Overview
• 25.2. Canada Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thrombocytopenia Market

• 26.1. South America Thrombocytopenia Market Overview
• 26.2. South America Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thrombocytopenia Market

• 27.1. Brazil Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thrombocytopenia Market

• 28.1. Middle East Thrombocytopenia Market Overview
• 28.2. Middle East Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thrombocytopenia Market

• 29.1. Africa Thrombocytopenia Market Overview
• 29.2. Africa Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thrombocytopenia Market Competitive Landscape And Company Profiles

• 30.1. Thrombocytopenia Market Competitive Landscape
• 30.2. Thrombocytopenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Thrombocytopenia Market Other Major And Innovative Companies

• 31.1. GSK Plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Merck & Co. Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Swedish Orphan Biovitrum AB
• 31.8. Argenx SE
• 31.9. GC Pharma
• 31.10. Biotest AG
• 31.11. UCB Biopharma
• 31.12. Rigel Pharmaceuticals
• 31.13. Millennium Pharmaceuticals
• 31.14. Keros Therapeutics Inc.
• 31.15. Baxalta

32. Global Thrombocytopenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thrombocytopenia Market

34. Recent Developments In The Thrombocytopenia Market

35. Thrombocytopenia Market High Potential Countries, Segments and Strategies

• 35.1 Thrombocytopenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Thrombocytopenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Thrombocytopenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer